This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

ADCETRIS provides a step change in treatment for Relapsed/Refractory Hodgkin lymphoma (R/R HL), Relapsed/Refractory systemic Anaplastic Large Cell Lymphoma (R/R sALCL) and CD30+ Cutaneous T-Cell Lymphoma (CTCL) after at least 1 prior systemic therapy1

ADCETRIS has received a conditional marketing authorisation in Europe

Treatment scenarios across multiple lines of therapy


ADCETRIS is indicated for the treatment of adult patients with CD30+2

  • Relapsed or refractory CD30+ Hodgkin lymphoma (HL):
    • following autologous stem cell transplant (ASCT), or
    • following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option
  • HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT)
  • Relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)
  • Cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy

Patient Support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed ADCETRIS

View patient support materials

Patient Support Booklet, PN Diary, PN Leaflet

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at

Adverse events should also be reported to Takeda on 01628 537900 or e-mail